University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Risk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICS

Simple item page
dc.contributor.authorPrice, David
dc.contributor.authorHenley, William
dc.contributor.authorDelfini Cançado, José Eduardo
dc.contributor.authorFabbri, Leonardo M
dc.contributor.authorKerstjens, Huib AM
dc.contributor.authorPapi, Alberto
dc.contributor.authorRoche, Nicolas
dc.contributor.authorŞen, Elif
dc.contributor.authorSingh, Dave
dc.contributor.authorVogelmeier, Claus F
dc.contributor.authorNudo, Elena
dc.contributor.authorCarter, Victoria
dc.contributor.authorSkinner, Derek
dc.contributor.authorVella, Rebecca
dc.contributor.authorSoriano, Joan B
dc.contributor.authorKots, Maxim
dc.contributor.authorGeorges, George
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2024-01-22T11:47:00Z
dc.date.available2024-01-22T11:47:00Z
dc.date.issued2024-01-20
dc.descriptionProfessor Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Jaco Voorham is acknowledged for his contribution to protocol development. We would also like to acknowledge Ms. Shilpa Suresh (MSc) of the Observational and Pragmatic Research Institute (OPRI), Singapore, for editorial and formatting assistance which supported the development of this publication. This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was funded by Chiesi Farmaceutici S.p.A.en
dc.description.statusPeer revieweden
dc.format.extent16
dc.format.extent5887981
dc.identifier283453637
dc.identifierdfd60b36-cd89-44e5-a30a-17ed53f0ad8e
dc.identifier.citationPrice, D, Henley, W, Delfini Cançado, J E, Fabbri, L M, Kerstjens, H AM, Papi, A, Roche, N, Şen, E, Singh, D, Vogelmeier, C F, Nudo, E, Carter, V, Skinner, D, Vella, R, Soriano, J B, Kots, M & Georges, G 2024, 'Risk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICS', Pragmatic and Observational Research, vol. 15, pp. 1-16. https://doi.org/10.2147/POR.S438031en
dc.identifier.doi10.2147/POR.S438031
dc.identifier.issn1179-7266
dc.identifier.urihttps://hdl.handle.net/2164/22609
dc.identifier.vol15en
dc.language.isoeng
dc.relation.ispartofPragmatic and Observational Researchen
dc.subjectinhaled corticosteroidsen
dc.subjectpneumoniaen
dc.subjectCOPDen
dc.subjectextrafine beclometasoneen
dc.subjectlong-acting bronchodilatorsen
dc.subjectR Medicineen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleRisk of pneumonia in patients with COPD initiating fixed dose inhaled corticosteroid (ICS) / long-acting bronchodilator (LABD) formulations containing extrafine beclometasone dipropionate versus patients initiating LABD without ICSen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Price_etal_POR_Risk_Of_Pneumonia_VoR.pdf
Size:
5.62 MB
Format:
Adobe Portable Document Format
Download

Collections

All research